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Universal precautions prevent hepatitis C virus transmission: A 54
month follow-up of the Belgian multicenter study. The isolation of
anti-hepatitis C virus (HCV) in hemodialyzed (HD) patients has been
repeatedly advocated to prevent nosocomial HCV transmission. We
evaluated the incidence of seroconversion for HCV in Belgian HD
patients, and demonstrate the complete prevention of HCV transmission
by adherence to the universal precautions advocated by the Centers for
Disease Control (Atlanta, GA, USA). All (N 5 963) HD patients from 15
units, none of which isolates anti-HCV positive patients, were tested by a
second or third generation enzyme-linked immunosorbent assay (with
confirmation by a second- or third-generation recombinant immunoblot
assay or the polymerase chain reaction) every 18 months from May 1991
to November 1995. Follow-up was available in 488 patients (drop-outs
resulting from death or transplantation mainly). The yearly incidence of
seroconversion for HCV over the initial 18 months was 1.41%, with
evidence suggestive of nosocomial HCV transmission. Universal precau-
tions were therefore reinforced. The incidence of seroconversion subse-
quently fell to 0.56% and 0%, respectively (P 5 0.014), despite the facts
that the average transfusion load and the proportion of patients with
dialyzer reuse or with monitors disinfected after each session did not
change significantly. We conclude that the strict enforcement of universal
precautions fully prevents HCV transmission to HD patients. The isola-
tion of anti-HCV positive patients is not warranted.
The unequivocal demonstration of a nosocomial transmission
of the hepatitis C virus (HCV) [1–3] to hemodialyzed (HD)
patients has initiated a debate on the preventive measures to be
taken in HD units [4].
Following the successful experience of segregation of hepatitis
B virus (HBV) (1) patients, which led to a drastic fall of HBV
transmission before the vaccination era [5], several authors have
advocated the isolation of anti-HCV (1) patients in a separate
HD room [1, 3, 6–9]. In sharp contrast, other authors [10–13]
have stressed that nosocomial transmission probably resulted
mainly from an inadequate application of the universal precau-
tions delineated by the Centers for Disease Control (Atlanta, GA,
USA) [14], and concluded that prevention of HCV nosocomial
transmission would be better achieved by strict adherence to the
universal precautions by staff members, than by the cumbersome,
not fully secure, segregation of patients.
We have taken advantage of an ongoing prospective Belgian
multicenter study to evaluate the benefits of the latter policy in the
absence of patient isolation. We demonstrate the full prevention
of HCV transmission.
METHODS
Hemodialysis units
All 15 units involved in the initial 18-month phase of the study
[10] accepted to participate for two further 18-month periods, for
a total follow-up of 54 months. A single small unit was closed as
of September 1993, and most of its patients were transferred to
another participating unit. None of the units isolated anti-HCV
(1) patients. As the results of the initial 18 month survey strongly
suggested nosocomial transmission of HCV [10], staff meetings
were held in participating units in order to explain the universal
precautions [14] and identify potential breaks in their implemen-
tation.
Patients
All patients given chronic hemodialysis either in hospital-based
or in low-care facilities were included. They were tested for
anti-HCV antibodies every 18 months from May 1991 to Novem-
ber 1995. Patients on home HD or peritoneal dialysis were not
included.
No patient was an intravenous drug abuser or had antibodies
against the human immunodeficiency virus.
Virologic tests
Screening. Screening was performed by second generation en-
zyme-linked immunosorbent assay (ELISA 2; Ortho Diagnostic
Systems, Raritan, NJ, USA) in May 1991 and November 1992, and
by the more sensitive [15, 16] third generation ELISA (ELISA 3;
Ortho) in May 1994 and November 1995.
In order to facilitate comparisons between the three consecu-
tive 18-month periods, only patients tested at these 18 month
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intervals were included. Thus, in contrast with our initial 18 month
study [10] in which patients were tested (and included) every six
months, patients tested only in November 1991 and/or May 1992
were not included.
Confirmation. ELISA 2 positive patients were tested by the
second-generation recombinant immunoblot assay (RIBA 2; Or-
tho). ELISA 3 positive patients were tested by the third genera-
tion RIBA [15] and/or the reverse transcriptase nested polymer-
ase chain-reaction (RT-PCR) for the detection of HCV-RNA
[17]. The detection of antibodies against at least one HCV antigen
or of HCV-RNA was considered as confirmatory. In order to
differentiate true seroconversion from an apparent seroconver-
sion resulting from the higher sensitivity of ELISA 3, the ELISA
2 (2) sera of patients who became subsequently ELISA 3 (1)
were retested by the ELISA 3.
Genotyping of HCV strains. All genotyping of the HCV strains
was performed by Inno-Lipa II [18].
Hemodialysis practices
Blood transfusions administered throughout the study were
recorded for each patient as previously described [10]. Each unit
was asked to fill in a form detailing HD practices such as the
frequency of disinfection of HD monitors and the existence of a
program of dialyzer reuse, during each 18-month period, and to
state the actual proportion of patients concerned.
Statistics
Standard statistical tests were performed as indicated. P val-
ues , 0.05 were considered as significant.
RESULTS
Patient characteristics
A total of 963 patients (545 males) were included. At the time
of inclusion, they had a median age of 60 years (range, 12 to 88
years old) and had been on HD for a median of 11 months (range,
, 1 to 257 months).
Follow-up of the included patients
Four hundred and eighty-eight patients were tested more than
once and were included in both the longitudinal and prevalence
studies. The other 475 were added to the prevalence study only, as
they were tested only once as a result of death (N 5 170), renal
transplantation (N 5 85), transfer to CAPD (N 5 4) or to
non-participating HD units (N 5 16), recovery of renal function
(N 5 3) or inclusion in November 1995 (N 5 197).
Incidence of seroconversion for hepatitis C virus
During the three consecutive 18-month periods, the yearly
seroconversion rate dropped from 1.41% (5 of 236 patients at
risk) to 0.56% (2 of 238 patients at risk) and 0% (0 of 269 patients
at risk) (X2 for trend, P 5 0.014).
The five seroconversions observed during the initial 18 months
were detected in three unrelated HD units: unit A, N 5 2; unit B,
N 5 2; unit C, N 5 1. The subsequent two seroconversions were
detected in two unrelated HD units: unit A and unit D. The
genotypes of HCV strains of patients with seroconversion from
units A and B were 1b, 4 and 4 c/d one each (unit A) and 1b for
both patients (unit B).
Prevalence of anti-hepatitis C virus positive patients
Anti-HCV antibodies persisted in all patients throughout the
follow-up period, for a total follow-up of 169 patient-years. The
prevalence of confirmed anti-HCV (1) patients dropped from
13.5% (54 of 399) in May 1991 to 11.8% (51 of 433) in November
1992, 12.7% (61 of 481) in May 1994 and 9.4% (48 of 510) in
November 1995. This drop in prevalence between May 1991 and
November 1995 barely reached significance (X2, P 5 0.0507).
Evolution of hemodialysis practices
During the three consecutive 18-month periods, no significant
change was observed in the percentage of patients with dialyzer
reuse (37, 37 and 35% respectively; X2 for trend, NS) and in that
of patients whose HD monitors were disinfected after each
session (25, 28 and 31%, respectively; X2 for trend, NS). The same
was true when only the percentage of involved units was consid-
ered (Table 1; X2 for trend, NS).
Blood transfusions
The number of blood transfusions administered to patients at
risk of seroconversion did not change during the three consecutive
periods: 1.4 6 3.7 (SD) unit/18 months/patient, 1.7 6 4.3 and 1.3 6
3.8, respectively (Mann-Whitney U-test, NS; Table 1). Of note,
three of the seven patients with seroconversion (2 of 5 and 1 of 2
during the first and second 18-month studies, respectively) had
not been transfused during the preceding 18 months.
DISCUSSION
In our multicenter study, the incidence of seroconversion for
HCV in HD patients fell progressively to zero over a 54 month
period. This observation is even more impressive as ELISA tests
were more sensitive in the last two periods than in the first one.
Table 1. Incidence of seroconversion and evolution of hemodialysis (HD) practices over three consecutive 18 month periods
May 91–Nov 92 Nov 92–May 94 May 94–Nov 95 P value
Incidence of seroconversion
yearly SC rate 1.41% 0.56% 0% 0.014
Dialyzer reuse
% of patients 88/236 (37%) 88/238 (37%) 95/269 (35%) NS
% of units 8/15 (53%) 9/15 (60%) 7/14 (50%) NS
Systematic disinfection of monitors
% of patients 58/236 (25%) 67/238 (28%) 83/269 (31%) NS
% of units 4/15 (27%) 5/15 (33%) 4/14 (29%) NS
Transfusion policy
units/18 months/patient 1.4 6 3.7 1.7 6 4.3 1.3 6 3.8 NS
(mean 6 SD)
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Admittedly, rare new HCV infection(s) might have been missed
by the ELISA tests, as recently reported in abstract form [19].
Still, in the few cases of unexplained alanine aminotransferase
increase, which were tested by PCR, HCV-RNA was not detected
(data not shown).
Possible explanations for our results should be discussed. Better
prevention of transfusional HCV transmission is not a likely
explanation as the average transfusional load did not change over
the three periods. Admittedly, the testing of blood donors im-
proved substantially over the 54 months, the first generation tests
being replaced by the more sensitive second and, eventually, third
generation tests. The risk of transfusional transmission of HCV
has clearly decreased with recent screening tests [20, 21]. How-
ever, three of the seven detected seroconversions occurred in
non-transfused patients; furthermore, our initial study strongly
pointed to nosocomial HCV infection in some of our patients [10].
Changes in dialyzer reuse are also unlikely to have contributed
to the fall of the incidence of HCV seroconversion. Dialyzer reuse
was not a risk factor for seroconversion over the initial 18-month
period [10]. Furthermore, in contrast to the progressive fall in the
incidence of seroconversion over the entire 54 months, the overall
reuse policy did not change, as illustrated by the stability of the %
of patients with reuse. Interestingly, most units with reuse do not
use a separate room for the reuse of dialyzers in HCV (1)
patients (data not shown), a finding in contrast with the recent
suggestion that the absence of this precaution may be a risk factor
for seroconversion [22].
The prevention of HCV transmission through contaminated
HD monitors is also unlikely to account for the decreasing
incidence of seroconversion. Indeed, no new case of HCV trans-
mission occurred despite an unchanged (and poor) disinfection
policy of monitors: over the 54 months, over 70% of the patients
were dialyzed in units whose monitors were not disinfected after
each session. This observation argues against a significant role of
monitors in HCV transmission at all!
The role of infected staff members as a significant source of
HCV infection for patients appears also unlikely. Indeed, the
number of HCV (1) nurses working in participating units de-
creased only slightly from six [23] to five (unpublished data) over
the last three years. In contrast, the incidence of HCV transmis-
sion dropped markedly. The recent demonstration of HCV trans-
mission from a surgeon to five of his patients [24] thus remains
unusual.
It might be argued that the trend towards a lower prevalence of
anti-HCV (1) patients was the factor that reduced the risk of
nosocomial transmission, and hence decreased the incidence of
seroconversion. This hypothesis does not account for our obser-
vations as the prevalence of anti-HCV (1) at the onset of the last
18 month period was 12.7%, similar to that at the onset of the
study (13.5%).
In the absence of a more convincing explanation, we propose
that the suppression of HCV transmission resulted from the
improved enforcement of universal precautions. Although adher-
ence to universal precautions was not quantitated in this long-
term multicentric study, it is noteworthy that the decrease in HCV
transmission coincided with the efforts to fully describe the
universal precautions to staff members as well as patients, and
improve their actual implementation in the participating units. A
special emphasis was laid upon hand washing, the use of gloves
and the avoidance of sharing of articles between patients. Our
results support the CDC statement that universal precautions
should prevent HCV transmission in HD patients [12], especially
as the infectivity of HCV is much lower than that of HBV. They
are also in line with the experience reported in abstract form by
the E. Rist Medical Center in Paris, where a 0% incidence has
been maintained over several years despite a high HCV preva-
lence and the absence of isolation [25].
The alternative policy to the strict implementation of universal
precautions is the isolation of anti-HCV (1) HD patients in a
separate room or on separate monitors. In 1993, these respective
policies were adopted by 18 and 37% of HD units from the
European Dialysis and Transplant Association Registry [26].
These percentages have increased more recently in Spain and
Portugal [22, 27].
The effectiveness of isolation in separate rooms remains to be
demonstrated. In Portugal, units isolating anti-HCV (1) patients
reported a rather high (3.2%) yearly incidence of seroconversion
in 1991 to 1993 (prevalence around 25%) [22]. The safety of
isolating anti-HCV (1) HD patients also remains unproved.
Indeed, as pointed out elsewhere [11], isolation entails the risk of
less than adequate implementation of universal precautions, with
an attendant higher risk of cross-infection by multiple HCV
strains and/or other viruses. In this regard preliminary results
suggest that the incidence of infection by the recently discovered
hepatitis G virus (HGV) also fell to zero in our unit in parallel
with that of HCV. Finally, isolation entails a substantial cost,
especially in units with HBsAg (1) patients, in which up to four
wards (to accommodate the B1C1, B1C2, B2C1, B2C2
patients) may be required.
The dedication of separate monitors for HCV (1) patients has
been advocated as an alternative. Two small single center studies
have recently reported a low (but not 0%) incidence of serocon-
version for HCV [28, 29] with this policy. The risks of cross-
infection are not avoided by this policy, and its large scale
effectiveness remains to be demonstrated. As the role of the
monitors in HCV transmission appears limited, the degree of
effectiveness of this policy is likely to depend mainly on the
associated improved application of universal precautions, the
segregation acting mainly as a reminder of the risk of viral
transmission.
Nosocomial transmission of HCV has recently been demon-
strated both in a hematology ward [30] and in renal transplant
recipients [31]. On the basis of our observations it may be
proposed that in these other, less exposed settings, prevention
should also rely mainly on an enforced adherence to universal
precautions.
In conclusion, we report the full prevention of HCV transmis-
sion to HD patients by implementing universal precautions, rather
than isolation of anti-HCV (1) patients.
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